Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of isoniazid 300 mg for latent tuberculosis treatment
RBR-2wsdt6Completed
- Sponsor
- Universidade Federal do Espírito Santo
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of isoniazid in latent tuberculosis infection (LTBI) (2 arms), sponsored by Universidade Federal do Espírito Santo. Started Jan 2019; status: completed.
02
Drugs
isoniazid
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on RBR-2wsdt6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-2wsdt6.